Beta Bionics Inc. (NASDAQ:BBNX) Chief Financial Officer Stephen Feider executed a series of stock transactions in late June, exercising employee stock options and selling the acquired shares under a pre-established trading arrangement. The CFO's activity involved the purchase and immediate sale of 10,000 shares of the company's common stock, a move conducted through a Rule 10b5-1 plan adopted on May 15, 2025.
On June 26, Feider exercised options for 5,104 shares at an exercise price of $5.10 per share. Two days later, on June 29, he exercised an additional 4,896 options at the same $5.10 per share cost. The total expenditure for these option exercises amounted to $51,000. These options were scheduled to vest in 48 equal monthly installments beginning September 14, 2023.
Concurrent with the option exercises, Feider sold the newly acquired shares. On June 26, he sold 5,104 shares at a weighted average price of $17.0467, with transaction prices ranging between $17.00 and $17.12. On June 29, he sold the remaining 4,896 shares at a weighted average price of $17.0304, with prices ranging from $17.00 to $17.08. The total proceeds from these sales reached approximately $170,387.
Following these transactions, Feider's direct holdings in Beta Bionics stand at 166,053 shares. He also retains beneficial ownership of 39,695 shares underlying employee stock options. The recent filing served as an amended Form 4, correcting the reported number of shares subject to option exercises and the final count of securities beneficially owned after the transactions.
These insider movements come as Beta Bionics reported first-quarter revenue of $27.6 million, a figure that surpassed Wall Street estimates by 2.5%. The company simultaneously raised its guidance for total revenue, gross margin, and the percentage of new patient starts through the pharmacy channel.
Analyst reactions to the earnings results varied in price target adjustments but generally maintained positive stances on patient metrics. Piper Sandler exceeded expectations across all metrics in its first-quarter assessment and maintained an Overweight rating, though it lowered its price target to $20.00 from $32.00. BofA Securities adjusted its price target to $23.00 from $28.00 while keeping a Neutral rating, citing a positive outlook on patient starts. Stifel lowered its price target to $20.00 from $22.00, maintaining a Buy rating and highlighting the company's strong gross margin of 59.5%. Lake Street reiterated a Buy rating and a $20.00 price target, acknowledging performance despite challenges in upfront revenue recognition.
The company also launched a public dashboard for its iLet Bionic Pancreas, providing real-world data on patient outcomes. As of the latest market data, Beta Bionics stock trades at $16.77, giving the company a market capitalization of $744 million. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value and currently shows strong recent momentum with a 5.34% gain over the past week. InvestingPro offers 8 additional exclusive tips for BBNX, along with comprehensive Pro Research Reports covering over 1,400 US equities.